department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Inqovi · pharmadog

pharmadog
drugs
Inqovi

drug

patient view →

(cedazuridine + decitabine)

Marketedupdated 2mo ago

by Otsuka Pharmaceutical Co Ltd

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Inqovi

generic

(cedazuridine + decitabine)

indication

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 7, 2027

~1.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Feb 24, 2041formulationUS 11963971
Feb 24, 2041method-of-use (U-2866)US 12239653
Oct 7, 2040formulationUS 12195496
Aug 22, 2030compositionUS 82688004.1y
Oct 16, 2028method-of-use (U-2867)US 86180752.3y
Oct 16, 2028compositionUS 95673632.3y

FDA exclusivities (1)

Jul 7, 2027ODE-316Orphan Drug (7y)1.0y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying (cedazuridine + decitabine)

EP1Early Intervention in High Risk CCUSrecruitingn=108
phase1Inqovi Maintenance Therapy in Myeloid Neoplasmsactive not recruitingn=22
phase2Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.active not recruitingn=33
phase2STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDSterminatedn=39